Claims
- 1. A method of promoting the proliferation of chondrocyte cells comprising contacting the at least one chondrocyte cell with a composition comprising at least one polypeptide, wherein the polypeptide is an OAX polypeptide.
- 2. The method described in claim 1 wherein the cells are mammalian cells.
- 3. The method described in claim 1 wherein the cells are human cells.
- 4. A method of treating an inflammatory pathology in a subject comprising administering to the subject a composition comprising a polypeptide wherein the polypeptide is an OAX polypeptide.
- 5. The method described in claim 4 wherein the subject is a mammal.
- 6. The method described in claim 4 wherein the subject is a human.
- 7. The method described in claim 4 wherein the polypeptide comprises an OAX polypeptide, wherein the OAX polypeptide comprises
a) SEQ ID NO:2, 4, 6, or 8; b) a variant of SEQ ID NO:2, 4, 6, or 8 wherein up to 15% of the residues provided in SEQ ID NO:2, 4, 6, or 8 are changed according to a conservative amino acid substitution; c) a deletion mutant of SEQ ID NO:2, 4, 6, or 8; or d) a variant of a deletion mutant of SEQ ID NO:2, 4, 6, or 8 wherein up to 15% of the residues provided in the deletion variant are changed according to a conservative amino acid substitution.
- 8. The method described in claim 4 wherein the inflammatory pathology is osteoarthritis.
- 9. The method described in claim 4 wherein the inflammatory pathology is an inflammatory condition occurring in the joint and joint space, and degeneration of the cartilage matrix and osteoarthritis.
- 10. The method described in claim 7 wherein the inflammatory pathology is an inflammatory condition is selected from the group consisting of inflammation of the joint and joint space, and degeneration of the cartilage matrix and osteoarthritis.
- 11. The method described in claim 7 wherein the polypeptide is administered to the subject intraperitoneally.
- 12. The method described in claim 7 wherein the polypeptide is administered to the subject intravenously.
- 13. The method described in claim 7 wherein the polypeptide comprises administered to the subject subcutaneously.
- 14. A method of promoting cartilage matrix repair in a subject comprising administering a OAX polypeptide.
- 15. The method described in claim 14 wherein the subject is a mammal.
- 16. The method described in claim 14 wherein the subject is a human.
- 17. A method of ameliorating a pro-inflammatory pathology in a subject comprising administering to the subject a composition said compositions comprising a combination of an OAX polypeptide, a growth factor, and a candidate therapeutic.
- 18. The method described in claim 17 wherein the subject is a mammal.
- 19. The method described in claim 17 wherein the subject is a human.
- 20. The method described in claim 17 wherein the composition is administered to the subject intravenously.
- 21. The method described in claim 17 wherein the composition is administered to the subject subcutaneously.
- 22. A method of preparing a pharmaceutical composition comprising combining at least one polypeptide effective in treating an inflammatory pathology with a pharmaceutically acceptable carrier, wherein the polypeptide is a OAX polypeptide.
- 23. The method described in claim 39 wherein the inflammatory pathology is osteoarthritis.
RELATED APPLICATION
[0001] This application claims the benefit of priority from U.S. Ser. No. 60/356,376 filed Feb. 12, 2002, the contents of which are incorporated herein in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60356376 |
Feb 2002 |
US |